Document:

wve-ex1092_563.htm

Exhibit 10.9.2

 

Amendment No. 1 to 

Research, License and Option Agreement

(“Amendment No. 1”)

 

	
Amendment No. 1
	
 
	
Date: November 5,  2017

	
 
	
 
	
 

	
Name of Original Agreement:
	
 
	
Research, License and Option Agreement (the “Original Agreement,” and together with any previous amendments which may be described below, the “Agreement”)

	
 
	
 
	
 

	
Effective Date of Original Agreement:
	
 
	
May 5th, 2016 (“Effective Date”)

	
 
	
 
	
 

	
Parties:
	
 
	
Pfizer Inc. (“Pfizer”) and Wave Life Sciences Ltd. (“Wave”)

	
 
	
 
	
 

	
Dates of Previous Amendment(s):
	
 
	
None.

 

WHEREAS, the parties hereto desire to amend certain terms of the Agreement in order to provide for an extension of the period of time to nominate the Additional Programs, 

 

NOW, THEREFORE, in order to accommodate the desired amendment(s), the parties hereby agree as follows:  

 

	
1.
	
Defined Terms.   Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.

 

	
2.
	
Amendment(s) to the Agreement.  

 

	
 
	
2.1.
	
Section 4.1.2 of the Agreement is hereby revised and replaced to read, in its entirety, as follows:

 

“Additional (3) Programs.  Pfizer will have the right (but not the obligation) to designate up to three (3) additional therapeutic targets, all three (3) of which will be hepatic targets directed toward hepatic therapeutic conditions (each, an “Additional Program”).    The total of up to three (3) Additional Programs will be designated by Pfizer by written notice to Wave within twenty four (24) months after the Effective Date.  The Additional Programs may be against any hepatic target directed toward hepatic therapeutic conditions of Pfizer’s choosing, provided that such hepatic target is not a Wave Reserved Target listed in Exhibit D and is not at the time of designation either: (1) the subject of a bona fide on-going Wave internal research program; or (2) the subject of a bona fide existing collaboration, license, option or asset purchase agreement between Wave and a Third Party.  Each such Additional Program may include Pfizer Technology or Wave Hepatic Targeting Technology, at Pfizer’s election”

 

 

 

	
3.
	
Ratification of the Agreement.  Except as expressly set forth in Article 2 above, the Agreement shall remain unmodified and in full force and effect.  The execution, delivery and effectiveness of this Amendment No. 1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver of any provision of the Agreement.

 

	
4.
	
Counterparts. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an original instrument and all of which, when taken together, shall constitute one and the same agreement.

 

 

IN WITNESS WHEREOF, the duly authorized representatives of Pfizer andWave have executed this Amendment No. 1 as of the date first above written.

 

	
Wave Life Sciences Ltd.
	
 
	
Pfizer Inc.

	
 
	
 
	
 

	
By:
	
 
	
/s/ Paul Bolno
	
 
	
By:
	
 
	
/s/ Morris J. Birnbaum

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Print Name:
	
 
	
Paul Bolno
	
 
	
Print Name:
	
 
	
Morris J. Birnbaum

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Title:
	
 
	
President and CEO
	
 
	
Title:
	
 
	
SVP, CSO, Internal Medicine

	
 
	
 
	
(Duly authorized)
	
 
	
 
	
 
	
(Duly authorized)

 

 

Page 2 of 2Exhibit 4.3

 

 

 [•], 2018

 

To

 

Mikroman Madencilik Mining

Hisarardi Koyo

Yatagan Mugla

Turkey

 

Dear Murat, Serhat, Karabay

 

Following our discussions, here are the terms agreed between us with respect to quartz supply on a nonexclusive basis by Mikroman to Caesarstone Ltd. and its subsidiaries and affiliates (collectively, "Caesarstone") for its utilization in Caesarstone's manufacturing facilities worldwide, starting Jan 1, 2018 and until December 31, 2018. Upon both parties' signing on at the bottom of this letter agreement (this "Letter Agreement"), it will constitute a binding framework agreement between Mikroman and Caesarstone, under which Caesarstone will be entitled (but not obligated) to submit purchase orders ("Purchase Orders"). Mikroman undertakes to comply with any applicable laws and regulations with respect to the Products and services provided herein.

 

1. Estimated Quantities and binding orders and supply

 

Caesarstone's working plan for year 2018 is as follows:

 

	
Product

	
Quantity 2018

	
1

	
*

	
*

	
2

	
*

	
*

	
3

	
*

	
*

	
4

	
*

	
*

	
5

	
*

	
*

	
6

	
*

	
*

	
7

	
*

	
*

	
8

	
*

	
*

 

The above is Caesarstone's working plan with a non-binding purchases projection from Mikroman for year 2018 (the "Estimated Quantities") for the abovementioned products (the "Products"). Caesarstone's actual orders may significantly differ from the Estimated Quantities. Caesarstone may deliver to Mikroman a binding Purchase Order on a monthly basis, and Mikroman shall be committed to supply to Caesarstone all such Purchase Orders (in accordance with the timeframe and Products' quality standards and specifications set in writing by Caesarstone at its sole discretion) up to the Estimated Quantities.

 

2. Prices – For actual quantities of the Products that shall be ordered by Caesarstone during year 2018, Mikroman will charge from Caesarstone the following:

 

For * – US$* (* US Dollars) per ton.

3. Payment terms – for Products that shall be ordered by Caesarstone during year 2018 payment terms shall be *.

 

4. The products will be supplied by Mikroman in a timely manner and in accordance with Caesarstone's quality standards, packing and delivery instructions and specifications as will be updated by Caesarstone in writing from time to time as Caesarstone's sole discretion, in accordance with each Caesarstone's purchase order. Any Purchase Order not delivered on time at its destination (Izmir Port FOB) shall entitle Caesarstone, at its own election, to cancel such Purchase Order (in addition to any right it may be entitled to) without any liability, unless such Purchase Order was delivered prior to the issuance by Caesarstone of a notice of cancellation, and Mikroman shall not have any claim with respect to such cancellation. Mikroman shall be fully responsible for any incompatibility or defects of the Products. Notwithstanding the aforementioned, Mikroman shall not be responsible only to such defects which were caused during and directly from the negligence or malfunctioning of the Product's forwarder. Upon indication of incompatibility in a Product identified by Caesarstone and notifies such incompatibility notification to Mikroman (an "Incompatibility Notification"), Mikroman shall be entitled to examine such Products at the applicable Facility within 30 days of receipt of the Incompatibility Notification; provided however, that it has notified Caesarstone in writing of its intention to conduct such examination within 10 days of receipt of the Incompatibility Notification. Thereafter, Mikroman shall be obliged to immediately, at Caesarstone's sole discretion, either: (1) replace such Product in the next shipment, or (2) issue a full refund/credit therefor. In addition Mikroman shall either collect the defected Products from the Facility within 45 days of Caesarstone's requirement, or pay Caesarstone's all costs and expenses incurred by it in relation to the disposal of such Products.

 

 

5. The parties will maintain in confidence the terms of this agreement as well as any other information delivered to each of them by the other party without time limitation. Notwithstanding the aforementioned, as Caesarstone is a public company traded on NASDAQ, Mikroman acknowledges and agrees that Caesarstone may be required to disclose certain information related to this agreement under any applicable law as shall be interpreted by Caesarstone at its sole discretion; accordingly, any confidentiality undertaking by Caesarstone set forth herein shall be subject to such Caesarstone's disclosure obligations and it is agreed herein that the aforementioned actions will not be deemed in any way a breach of Caesarstone's confidentially undertaking set forth above.

 

6. This agreement and its performance will be governed by the English law and subject to the jurisdiction of the competent courts in England. Without derogating from the generality and validity of the foregoing, Caesarstone shall be entitled, at its sole discretion, to initiate legal proceedings related to this Agreement in Turkey, and in such case only same proceeding will be subject to the jurisdiction of the competent courts in Turkey.

 

7. This Agreement constitutes the entire agreement between Mikroman and Caesarstone, and all prior agreements, understandings and/or commitments of any of the parties, whether in writing or verbal, with respect to the matters covered herein are superseded and null.

 

8. As Caesarstone is a public company traded on NASDAQ, Mikroman  is aware (and that its representatives who are apprised of this matter have been or will be advised) that U.S. securities laws restrict persons with material non-public information about a company obtained directly or indirectly from that company from purchasing or selling securities of such company and from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities.  Mikroman agrees to comply with such laws and recognizes that Caesarstone will be damaged by his non-compliance.  In addition, Mikroman hereby acknowledges that unauthorized disclosure of confidential information may be in violation of the securities laws.

 

9. Each party may not assign, delegate or transfer this Agreement or any of its obligations hereunder, without the prior written consent of the other party.

 

10. Any amendment or modification of this Agreement shall be effective if mutually agreed upon by the parties, made in writing and constituted an appendix as an integral part of the Agreement.

 

Please indicate your agreement with the above terms by signing both counterparts of this Letter Agreement as provided below and return one fully executed copy to us.

 

/s/ By: Raanan Zilberman, Yair Averbuch

Caesarstone Ltd.

By: Raanan Zilberman, Yair Averbuch

Title: CEO, CFO

Date: 21.1.2018

 

	
 

	

We hereby approve our consent to all of the above.

/s/ Serhat Saran          

Mikroman Maden San. Ve Tie A.S.

By: Serhat Saran

Title: Member of Board

Date: 2.1.2018

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]